Pricing Log in Create free account
Wednesday 4 November 2026 Export EDIT’s income statement to Excel — free account

Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024.

Revenue
+232.3%
EPS
+76.2%
Free cash flow
+40.7%

Quarter to June 2026, against a year earlier

2.71 0.11 +4.23%
Market cap
$399.3M
P/E
0.0×
Fwd P/E
−3.4×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.11
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 3 — — 3 — — 3 1 1 3 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 399.31
Revenue ttm 47.01
Net income ttm (73.95)
Free cash flow ttm (120.28)
Net debt Q (211.64)
Valuation
P/E 0.00
Forward P/E (3.41) (negative: loss-making)
Price / sales 6.60
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.95
Financial health
Current ratio Q 3.19 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (17.49)
Growth
Revenue growth Q +232.31% (above 0%: growing)
Operating income growth Q +64.00% (above 0%: growing)
EPS, this year +56.82% (at or above 15%: strong)
EPS, next year A +8.67%
Revenue, next year A −36.35% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +25.35% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 23.1×; over the ten years it ranged from −4.1× in 2024 to 250× in 2016.
P/S against its own 10 years 17.26%
10-year low 10-year high
P/B against its own 10 years 35.27%
10-year low 10-year high
EV/Sales against its own 10 years 11.53%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 323 270 147 212
Receivables 10 16 15 3
Inventory — — — —
Other — — — —
341 289 164 218
2023 2024 2025 Q'26
Payables 8 5 3 5
ST’ Debt — — — —
Other — 5 5 8
63 77 46 68

Compound Annual Growth %

10y 5y 3y
Sales 37.90% (14.89%) 27.15%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (13.53%) (41.36%) (57.71%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.30 Actual −0.15

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.38 −0.28 Beat by 0.10
Q4 FY25 −0.27 −0.06 Beat by 0.21
Q1 FY26 −0.30 −0.26 Beat by 0.04
Q2 FY26 −0.30 −0.15 Beat by 0.15
Q3 FY26 −0.21 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.26) (0.15) — — —
’25 (0.92) (0.63) (0.28) (0.06) (1.80)
’24 (0.76) (0.82) (0.75) (0.55) (2.88)
’23 (0.71) (0.56) (0.55) (0.23) (2.02)
’22 (0.74) (0.78) (0.81) (0.88) (3.21)
’21 (0.86) (0.81) (0.57) (0.61) (2.85)
’20 (0.69) (0.43) 0.12 (1.00) (1.98)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3 12 — — —
’25 5 4 8 25 41
’24 1 1 0 31 32
’23 10 3 5 60 78
’22 7 6 0 7 20
’21 6 0 6 12 26
’20 6 11 63 11 91
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (30) — — —
’25 (48) (50) (31) (36) (165)
’24 (50) (57) (53) (51) (210)
’23 (36) (39) (35) (22) (132)
’22 (49) (38) (48) (42) (177)
’21 (49) (39) (41) (35) (164)
’20 (54) (31) (55) (40) (180)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (30) — — —
’25 (48) (50) (31) (36) (166)
’24 (52) (61) (56) (51) (219)
’23 (38) (40) (36) (24) (137)
’22 (51) (38) (49) (43) (181)
’21 (50) (42) (43) (37) (172)
’20 (56) (33) (57) (41) (187)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 14 32 21 91 26 20 78 32 41 47 +23.5% 26 19 15 (27.5%)
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (97) (120) (110) (134) (116) (193) (220) (153) (237) (160) (74) +5.7%
EBT margin, % (1,605.53) (876.49) (344.28) (651.43) (127.82) (753.61) (1,118.26) (196.13) (733.72) (395.01) (157.32) +1,210.5 pt
Net income (97) (120) (110) (134) (116) (193) (220) (153) (237) (160) (74) +5.7%
Per share, $
Per share, $ Revenue 0.19 0.34 0.68 0.41 1.55 0.38 0.29 1.03 0.39 0.46 0.39 +10.4%
Earnings (3.02) (2.98) (2.33) (2.68) (1.98) (2.85) (3.21) (2.02) (2.88) (1.80) (0.75) (5.6%)
Cash flow (1.56) (0.23) (0.97) (0.81) (3.07) (2.42) (2.58) (1.74) (2.55) (1.86) (1.00) +2.0%
Capex (0.11) (0.05) (0.10) (0.12) (0.12) (0.12) (0.06) (0.06) (0.11) 0.00 0.00 (31.0%)
Free cash flow (1.67) (0.28) (1.07) (0.93) (3.19) (2.54) (2.64) (1.80) (2.66) (1.87) (1.01) +1.3%
Book value 4.18 5.16 5.01 5.25 6.72 8.19 5.25 4.60 1.63 0.31 0.88 (25.2%)
Shares, m 32 40 47 50 59 68 69 76 82 89 99 +11.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 90.70 100.81 33.55 72.09 45.29 70.28 29.40 9.70 3.24 4.49 6.60 46.0
P/B 4.08 6.65 4.54 5.64 10.44 3.24 1.61 2.17 0.78 6.67 2.95 4.6
EV/Sales 65.89 79.27 23.01 51.40 41.21 51.98 13.58 5.98 (4.11) 1.67 2.79 33.0
EV/FCF (7.42) (94.95) (14.58) (22.58) (20.00) (7.73) (1.48) (3.41) 0.61 (0.41) (1.09) (17.2)
Cash, $m
Cash, $m Operating cash flow (50) (9) (46) (41) (180) (164) (177) (132) (210) (165) (120) +14.1%
Capex (3) (2) (5) (6) (7) (8) (4) (5) (9) 0 0 (22.8%)
Free cash flow (54) (11) (50) (47) (187) (172) (181) (137) (219) (166) (120) +13.3%
Balance, $m
Balance, $m Working capital 154 295 339 404 361 460 297 278 212 118 150 (3.0%)
Net debt (150) (296) (337) (457) (402) (500) (344) (323) (270) (147) (212) (0.3%)
Shareholders’ equity 135 208 236 262 394 554 361 349 134 27 105 (16.2%)
Returns, %
Returns, % ROA (51.37) (39.95) (27.71) (28.79) (21.45) (30.80) (36.99) (30.24) (56.40) (60.61) (33.02) (9.2) pt
ROIC 0.00 0.00 0.00 0.00 0.00 (224.39) (860.78) (406.90) 0.00 0.00 0.00 0.0 pt
ROE (377.64) (70.22) (49.50) (53.65) (35.36) (40.65) (48.22) (43.17) (98.10) (198.14) (118.82) +179.5 pt
People
People Employees 89 112 133 208 235 264 226 265 246 87 — (0.3%)
Revenue/emp, $m 0.07 0.12 0.24 0.10 0.39 0.10 0.09 0.29 0.13 0.47 — +23.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Editas Medicine, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RLMD Relmada Therapeutics, Inc. $455.5M — (loss-making) — — n/m −50.06% (below 0%: shrinking) 0.00% 0.00% Compare
ASMB Assembly Biosciences, Inc. $405.6M — (loss-making) — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%) Compare
EDIT Editas Medicine, Inc. $399.3M — (loss-making) — (loss-making) +232.31% (above 0%: growing) n/m +40.72% (above 0%: growing) 100.00% (156.05%)
ALT Altimmune, Inc. $396.8M — (loss-making) — (loss-making) +520.00% (above 0%: growing) n/m −25.27% (below 0%: shrinking) 100.00% 0.00% Compare
CCCC C4 Therapeutics, Inc. $394.9M — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m +86.84% (above 0%: growing) 100.00% (397.88%) Compare
BLSM BlossomHill Therapeutics, Inc. $394.5M — (loss-making) — — n/m — — 0.00% Compare
AVTX Avalo Therapeutics, Inc. $388.8M — (loss-making) — (loss-making) −70.14% (below 0%: shrinking) n/m +75.70% (above 0%: growing) 55.73% 0.00% Compare
ZURA Zura Bio Limited $384.3M — (loss-making) — — n/m −26.22% (below 0%: shrinking) — 0.00% Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $376.6M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%) Compare
Median of peers $394.7M — — +38.94% — +7.58% 77.87% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2026

Ownership

Directors and executive officers, together 3.10%
The Vanguard Group, Inc. 6.80%
BlackRock Inc. 6.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Editas Medicine, Inc. (EDIT) Latest News

14 Oct

Impact 3 · · GlobeNewswire

9 Oct

Impact 4 · · Zacks

8 Oct

Impact 4 · · Stocktwits
Impact 4 · · GlobeNewswire

11 Sep

Impact 4 · · MarketBeat

9 Sep

Impact 4 · · MarketBeat

6 Aug

Impact 3 ·

5 Aug

Impact 4 ·

26 May

Impact 3 · · GlobeNewswire
Impact 3 · · GlobeNewswire
Impact 3 · · GlobeNewswire

6 May

Impact 3 · · Zacks

5 May

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

27 Mar

Impact 4 · · GlobeNewswire

17 Mar

Impact 4 · · The Motley Fool

15 Mar

Impact 4 · · MarketBeat

10 Mar

Impact 3 · · Zacks

9 Mar

Impact 3 · · Zacks
Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

9 Feb

Impact 3 · · Simply Wall St.

10 Dec

Impact 3 · · Zacks

25 Nov

Impact 3 · · Zacks

20 Nov

Impact 4 · · ZacksMT NewswiresSimply Wall St.Simply Wall St.MT NewswiresMT Newswires
Impact 3 · · Business Wire

18 Nov

Impact 4 · · Zacks

13 Nov

Impact 4 · · Simply Wall St.

11 Nov

Impact 3 · · ZacksZacksAssociated Press Finance

10 Nov

Impact 3 ·
stockrow.com/EDIT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com